Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B-cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is un...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4059833/
https://ncbi.nlm.nih.gov/pubmed/22698399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.05.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados